Abstract: Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research.
Introduction: Addressing the Global Burden of Cardiovascular Disease
Cardiovascular disease (CVD), particularly atherosclerosis and subsequent thrombosis, remains a leading cause of global mortality. While current diagnostic and therapeutic tools exist, they often face limitations. Traditional antibody-based diagnostics can be unstable and costly, while standard antiplatelet and anticoagulant therapies frequently carry a high risk of uncontrolled bleeding.
There is an urgent need for a "theranostic" approach—agents capable of simultaneous ultra-sensitive early diagnosis (e.g., detecting troponin levels during a heart attack) and targeted treatment with minimized side effects.
Methodology: The SELEX Process and Aptamer Engineering
Aptamers are single-stranded oligonucleotides (DNA or RNA) that fold into unique three-dimensional structures to bind specific targets with high affinity, often rivaling antibodies. The primary method for discovering these "chemical antibodies" is SELEX (Systematic Evolution of Ligands by Exponential Enrichment).
SELEX involves an iterative cycle of incubation, selection, and amplification. Beyond basic discovery, the review highlights advanced integration techniques:
- Aptasensors: Utilizing nanotechnology (e.g., gold nanoparticles, MoS2) and CRISPR/Cas12a for electrochemical or fluorescent detection.
- SOMAscan: A proteomic platform using modified aptamers (SOMAmers) to identify novel biomarkers in human plasma.
- Functionalized Stents: Coating drug-eluting stents with aptamers to capture Endothelial Progenitor Cells (EPCs), accelerating vessel healing.
Key Insights: Precision and Safety in Cardiac Care
The "Antidote" Advantage
A unique feature of aptamers is their reversibility. Because they are nucleic acids, their activity can be rapidly neutralized by administering a complementary "antidote" sequence. This provides a critical safety mechanism in surgical settings, allowing clinicians to instantly "turn off" an anticoagulant to prevent hemorrhage.
Targeting Von Willebrand Factor (vWF)
vWF is a crucial mediator between damaged blood vessels and platelet aggregation. The paper emphasizes that aptamers targeting vWF (such as ARC1779 or BT200) can inhibit clot formation more precisely than traditional drugs, significantly reducing bleeding risks in conditions like cerebral thromboembolism.
Key Results and Clinical Potential
- Ultra-sensitive Diagnostics: Modern aptasensors have achieved detection limits for Cardiac Troponin I (cTnI) as low as 10 fM (40 pg/ml), facilitating earlier heart attack detection.
- Biomarker Discovery: Proteomic studies using aptamers have identified 83 potential biomarkers for heart failure, correlating specific proteins with coronary artery disease burden.
- Clinical Success: The anti-vWF aptamer ARC1779 has successfully demonstrated reduced thromboembolism in carotid surgery patients with a superior safety profile compared to standard GPIIb/IIIa inhibitors.
Limitations and Future Directions
While promising, several challenges remain for widespread clinical adoption. Transitioning aptasensors from lab settings to complex human blood samples requires further refinement to overcome the "matrix effect." Additionally, small aptamers are prone to rapid renal clearance; chemical modifications like PEGylation are being optimized to balance stability and clearance. Finally, the cost of synthesizing highly modified aptamers currently remains higher than many small-molecule drugs.
The authors conclude that the next decade will likely see the integration of diagnosis and therapy, leveraging aptamers to advance precision cardiovascular medicine.
Summary updated